Belief Map

Sic IVE	DO MORE FOR MORE				
STRATEGIC	AWARENESS HCP EDUCATION	ADOPTION HCP ACTIVATION			ADHERENCE PATIENT ACTIVATION
	AWARENESS	DIFFERENTIATION	UTILIZATION	MOTIVATION	EMPOWERMENT
ENGAGEMENT STRATEGY	Establish the value of IFN gene screening	Champion measures of success that are relevant to clinical practice	Underscore the value of a non- exclusionary approach to management	Educate on the need for an optimal long-term management strategy for lupus	Help patients re-engage in their treatment and restore their partnership with HCPs
RATIONALE	There are no predictors of response for the biologic class	It's difficult to define treatment success for SLE	Current biologic ignores largest patient segment	HCPs recognize the drawback of current SoC	Moderate-to-severe patients feel let down by their physicians
CURRENT MINDSET	It's hit or miss with my biologic	I have a gut feeling that things are working; however, I prefer to rely on hard numbers when I can get them	I wish I had a biologic for my female patients of African descent	I rely on corticosteroids and ISs for long-term management of Iupus. It's a necessary evil, but I have no choice.	When SLE was finally diagnosed, I felt a great sense of relief. Now I feel like I'm not being heard again
DESIRED MINDSET	I know exactly which patients are most likely to respond	I'm convinced that anifrolumab is working based on these endpoints that matter to me	Finally, I can offer these long- deserving patients the highest standard of care	Finally I don't have to compromise safety for efficacy in the long-run	I can trust my rheumatologist again and rely on him or her to help me feel better
CURRENT BEHAVIOR	Rx as last resort in all severe patients	Keep patients on their current biologic indefinitely	Rx Benlysta for patients who failed in clinical trials because they have no other option	Extensive reliance on a cocktail of corticosteroids and ISs to manage both flares and long-term disease progression	Non-compliant. Self-medicating. Withdrawn
DESIRED BEHAVIOR	Actively screen IFN-high gene patients for biologic consideration	Actively switch or add anifrolumab to uncontrolled patients	Consistently turn to anifrolumab as the first-line therapy when a biologic is considered	Proactive use of anifrolumab before rapid steroid escalation and prior to ISs	Compliant and actively engaged with HCP treatment plan